- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01198132
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly (CHOLINE)
May 9, 2017 updated by: Merck KGaA, Darmstadt, Germany
A Multicentre, Randomised, Double-blind, Placebo-controlled Study of the Efficacy of Supplementary Treatment With Cholecalciferol (Vitamin D3) in Patients With Relapsing- Multiple Sclerosis (RMS) Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
The aim of this multicentre, randomised, double-blind, placebo-controlled study is to evaluate the efficacy and safety of supplementary treatment with cholecalciferol (vitamin D3) in subjects with relapsing multiple sclerosis (R MS) treated with subcutaneous (s.c.) interferon beta-1a 44 microgram (mcg) [Rebif] 3 times weekly.
The subjects will be divided into 2 groups, one receiving cholecalciferol 100,000 IU twice monthly along with Rebif treatment and the other group will be on placebo along with Rebif treatment.
A total of 200 subjects will be recruited in 20-30 centres in France.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
129
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Montpellier, France
- CHU Hôpital Gui de Chauliac Service de Neurologie B
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of RRMS according to Poser criteria (clinically definite multiple sclerosis [CDMS] or laboratory supported definite multiple sclerosis [LSDMS]) or according to McDonald criteria (2005).
- Subjects aged between 18 and 65 years.
- Treated with interferon beta-1a 44 mcg (or 22 mcg in case of intolerance to 44 mcg) 3 times weekly subcutaneously for 4 months ± (2 months) at the randomization visit (V1).
- Expanded disability status scale (EDSS) score between 0 and 5.
- At least one documented episode during the last two year.
- Stable disease with no episodes over the last 30 days.
- Serum 25-hydroxyvitamin D less than (<) 75 nanomolar per liter (nmol/l) at randomization visit.
Women must not be pregnant or breast-feeding, and women of childbearing age must meet the following criteria:
- Surgically sterilised, or
- Using a highly effective contraceptive method throughout the entire duration of the study. A highly effective contraceptive method is defined as a method with a very low failure rate (i.e. < 1 % per year) with regular and appropriate use, e.g. implants, injectable contraceptives, combined oral contraceptives, coil, abstinence or vasectomised partner.
- Menopausal women may be included.
- Affiliated to French healthcare insurance.
- Subjects must be ready and able to provide informed consent and comply with the protocol requirements.
Exclusion Criteria:
- Hormonal abnormalities associated with vitamin D other than low dietary intake or reduced exposure to sun, for example malabsorption (coeliac disease, Whipple's disease, inflammatory bowel disease, intestinal derivation, short bowel syndrome), cirrhosis, nephrotic syndrome, hyperthyroidism, rickets, hypoparathyroidism, cancer, granulomatous diseases (sarcoidosis, silicosis) and lymphomas known at the initial visit.
- Patients with osteoporosis or known osteopenia.
- Use of medicines affecting vitamin D metabolism other than corticosteroids, e.g. anticonvulsants (phenobarbital, primidone, phenytoin), rifampicin, isoniazid, ketoconazole, 5-FU and leucovorin, or thiazide diuretics.
- Previous or ongoing hypercalcaemia.
- Situations involving increased susceptibility to hypercalcaemia, e.g. known cardiac arrhythmia or cardiac disease, treatment with digitalis, renal lithiasis.
- Any contraindication to the treatment (cholecalciferol) stated in the summary of product characteristics.
- Moderate renal impairment defined as creatinine clearance between 30 and 60 ml/min.
- An active episode during the month prior to inclusion in the study.
- Inadequate liver function, defined as total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase greater than (>) 2.5 * upper limit of normal.
- Severe renal impairment defined as creatinine clearance below 30 milliliter per minute (ml/min).
- Inadequate marrow reserves, defined as white blood cells < 0.5 * lower limit of normal.
- Serious or acute heart disease such as uncontrolled cardiac arrhythmia, uncontrolled angina, cardiomyopathy or uncontrolled congestive heart failure.
- History of severe depression, or attempted suicide or ongoing suicidal ideation.
- Epilepsy inadequately controlled by treatment.
- Ongoing or previous alcohol or drug abuse (within the last two years).
- Major medical or psychiatric disease which, in the opinion of investigator, would place the subject at risk or could adversely affect compliance with the study protocol.
- Known hypersensitivity to gadolinium and/or known inability to undergo MRI.
- Any medical condition requiring chronic treatment with systemic corticosteroids.
- Participation in any other studies involving other study products over the 30 days prior to inclusion in this study.
- Legal incapacity or limited legal capacity.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cholecalciferol
Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 3 times a week.
|
Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 44 mcg 3 times a week.
Other Names:
Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Subjects receive matching placebo to Cholecalciferol once every two weeks along with subcutaneous injection of Rebif 3 times weekly.
|
Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
Other Names:
Subjects receive matching placebo to Cholecalciferol once every two weeks orally along with subcutaneous injection of Rebif 44 mcg 3 times weekly.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Annualized Relapse Rate
Time Frame: 2 years post treatment (IMP) administration
|
The annualized relapse rate was calculated for each treatment group as follows: the number of relapses observed during the study period divided by the time spent in the study (in years).
|
2 years post treatment (IMP) administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to First Documented Relapse
Time Frame: 2 years post treatment (IMP) administration
|
Time to First Documented Relapse was calculated using Kaplan-Meier survival methods.
|
2 years post treatment (IMP) administration
|
Mean Number of Relapses Per Subject
Time Frame: 2 years post treatment (IMP) administration
|
Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.
Mean and standard deviation were reported.
|
2 years post treatment (IMP) administration
|
Number of Relapse-Free (Documented) Subjects
Time Frame: 2 years post treatment (IMP) administration
|
The relapse-free patients after 2 years of treatment was calculated using Cochran-Mantel-Haenszel test using the site as control variable.
|
2 years post treatment (IMP) administration
|
Cumulative Probability of Progression of Disability (Kaplan-Meier Curves)
Time Frame: Baseline up to week 96
|
Disability progression was assessed using Expanded disability status scale (EDSS).
EDSS assesses disability in 8 functional systems.
An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.
A one-point increase on the EDSS scale was considered as a progression in disability.
The time to disability progression was summarized using Kaplan-Meier survival methods.
The cumulative probability of confirmed disease progression at each visit was obtained by applying a Kaplan-Meier method to the time to confirmed disease progression.
|
Baseline up to week 96
|
Number of New or Extended Lesions by T1- and T2-Weighted Magnetic Resonance Imaging (MRI)
Time Frame: 2 years post treatment (IMP) administration
|
2 years post treatment (IMP) administration
|
|
Changes From Baseline in Measured Lesion Load (T2)
Time Frame: Baseline, Week 96
|
Baseline defined as last value recorded prior to first intake of study drug.
|
Baseline, Week 96
|
Change From Baseline in Measurement and Evaluation of Cognitive Ability by Paced Auditory Serial Addition Task (PASAT) Total Score At Week 96
Time Frame: Baseline, Week 96
|
The Adapted Paced Auditory Serial Addition Task (PASAT) is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability.
The total score for PASAT is the total number of correct answers (out of 60, for a total possible score ranging from 0-60 with higher score indicates higher auditory processing speed) for each trial.
Change from baseline in PASAT total score at Week 96 was summarized.
|
Baseline, Week 96
|
Change From Baseline in Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L)
Time Frame: 2 years post treatment (IMP) administration
|
The EQ-5D health questionnaire is a generic self-reported health-related quality of life instrument that includes a 100 mm Visual Analog Scale (VAS) to measure the general health state, as well as 5 items corresponding to one dimension each: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
In this study, the VAS scale is not collected and the version 3L of the scale was used: Each dimension had 3 possible levels: 1 = no problem, 2 = some problems and 3 = extreme problems.
EQ-5D-3L weighted health state index exists that combines the score of the 5 dimensions and ranges from 0 to 1 (full health).
The variables for the 5 dimensions of the EQ-5D descriptive system was named 'mobility','selfcare', 'activity', 'pain', and 'anxiety'.
The 5 variables contained the values for the different dimensions in the EQ-5D health profile (i.e. 1, 2, or 3).
|
2 years post treatment (IMP) administration
|
Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Abnormal Clinical Laboratory
Time Frame: Baseline up to end of treatment (week 96)
|
A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect and TEAE was defined as newly occurring or worsening after first dose.
Clinical laboratory abnormalities are expected to be reported as adverse events if they met any criterion for seriousness, led to treatment discontinuation, required a medical intervention or were considered clinically significant by the investigator.
|
Baseline up to end of treatment (week 96)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 1, 2009
Primary Completion (ACTUAL)
March 1, 2015
Study Completion (ACTUAL)
November 1, 2015
Study Registration Dates
First Submitted
September 8, 2010
First Submitted That Met QC Criteria
September 8, 2010
First Posted (ESTIMATE)
September 9, 2010
Study Record Updates
Last Update Posted (ACTUAL)
December 14, 2017
Last Update Submitted That Met QC Criteria
May 9, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Micronutrients
- Adjuvants, Immunologic
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Interferons
- Interferon beta-1a
- Vitamin D
- Cholecalciferol
- Vitamins
- Ergocalciferols
- Interferon-beta
Other Study ID Numbers
- 701068-524
- 2009-013695-46 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Cholecalciferol (Vitamin D3)
-
Medical University of South CarolinaThrasher Research FundCompletedVitamin D Deficiency | PregnancyUnited States
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Mahidol UniversityUnknownCritical Illness | Vitamin D Deficiency | SarcopeniaThailand
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
University of California, San FranciscoCompletedUlcerative Colitis (UC) | Crohn's Disease (CD)United States
-
Sanjay Gandhi Postgraduate Institute of Medical...CompletedPancreatitis, ChronicIndia
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceTerminatedSystemic Lupus ErythematosusUnited States
-
Atlanta VA Medical CenterCompletedVitamin D Deficiency | Chronic Kidney DiseaseUnited States
-
University of California, San FranciscoCompleted